Press Release of Published Study
CEDAR KNOLLS, N.J., July 7, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today, the publication of a study that evaluated the impact of Fortetropin on the rate of muscle protein synthesis in older adults.
The peer reviewed study titled, "Effects of Fortetropin® on the rate of muscle protein synthesis in older men and women: a randomized, double blinded, placebo-controlled study," published in the Journal of Gerontology: Medical Sciences, reports results from a randomized, double-blind, placebo-controlled human clinical study involving 10 men and 10 women (60-75 years of age) conducted by researchers at the University of California, Berkeley and the University of Arkansas for Medical Sciences. The study can be found here.
In this clinical study, the 20 men and women consumed either Fortetropin or a macronutrient-matched placebo for 21 days along with daily doses of a heavy water tracer. After 21 days, a muscle biopsy was collected from each subject and analyzed to determine the rate of synthesis of multiple muscle proteins. For subjects who received Fortetropin, the average muscle protein synthesis rate was significantly (18%) higher compared to the placebo group.
"This study shows Fortetropin's remarkable potential for managing age-related muscle loss in older adults. The results from this clinical study will form the cornerstone of MYOS' 'Healthy Aging' Business," commented Joseph Mannello, Chief Executive Officer of MYOS. "In May 2020, we announced a commercial partnership with BodyLogicMD, one of the largest nationwide networks of anti-aging medical practices in the United States.
As part of this partnership, we co-developed a Fortetropin-based nutrition product, BodyLogicMD Muscle Health Formula with BodyLogicMD that will leverage results from this publication along with four other peer reviewed studies that have been published to date on Fortetropin," added Mr. Mannello.
"Fortetropin clearly has a robust effect on the rate of muscle protein synthesis in older adults. It is rare for a nutrition product to show such a consistent and positive effect. We look forward to continued scientific collaboration with MYOS," stated Dr. Evans.
Investor Relations:
MYOS RENS Technology
Joanne Goodford
Phone: 973-509-0444
Email: jgoodford@myoscorp.com
SOURCE: CISION (PRNewsWire)
Related Links